Remembering emil von behring: From tetanus treatment to antibody cooperation with phagocytes

49Citations
Citations of this article
128Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

A century ago, Emil von Behring passed away. He was the first to be honored by the Nobel Prize for Medicine in 1901 for the successful therapy of diphtheria and tetanus, which he had developed from the bench to the bed. He also contributed to the foundation of immunology, since his therapy was based on passive immunization with specific antisera. Being an ambitious character, he did not shy away from friction with his colleagues Paul Ehrlich and Elias Metchnikoff and his mentor, Robert Koch. Behring was not only an excellent translational researcher but also a successful entrepreneur and early proponent of public-private partnerships.

Cited by Powered by Scopus

Phage Display Derived Monoclonal Antibodies: From Bench to Bedside

185Citations
N/AReaders
Get full text

Immunology's coming of age

93Citations
N/AReaders
Get full text

History of envenoming therapy and current perspectives

86Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Kaufmann, S. H. E. (2017, January 1). Remembering emil von behring: From tetanus treatment to antibody cooperation with phagocytes. MBio. American Society for Microbiology. https://doi.org/10.1128/mBio.00117-17

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 42

78%

Researcher 8

15%

Professor / Associate Prof. 3

6%

Lecturer / Post doc 1

2%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 23

44%

Immunology and Microbiology 15

29%

Medicine and Dentistry 8

15%

Agricultural and Biological Sciences 6

12%

Article Metrics

Tooltip
Mentions
References: 6

Save time finding and organizing research with Mendeley

Sign up for free